Table 4.

Multivariate Analysis Between Paxlovid Use and Clinical Recovery

	HR*adj.	95% CI	p	HR†adj.	95% CI	p
Paxlovid use			0.472			0.512
Negative use	1.00	—		1.00	—
Use beyond five days of symptom onset	0.85	0.48, 1.49		0.89	0.49, 1.62
Single use within five days of symptom onset	1.61	0.75, 3.42		1.69	0.73, 3.94
Combining use with dexamethasone within five days of symptom onset	1.69	0.47, 6.09		2.18	0.29, 16.62
Age	0.99	0.98, 0.99	0.037	0.99	0.98, 0.99	0.036
Gender			0.634			0.519
Female	1.00	—		1.00	—
Male	0.92	0.64, 1.31		0.88	0.61, 1.29
Clinical classification of COVID-19			0.663		—
Mild and moderate illness	1.00	—
Severe and critical illness	1.19	0.55, 2.55
Cycle threshold value	0.98	0.95, 1.01	0.169	0.98	0.95, 1.01	0.173
Comorbidities			0.005			0.009
No	1.00	—		1.00	—
Yes	0.54	0.35, 0.83		0.56	0.36, 0.86

Notes: *All subjects, ^†Subjects with mild and moderate illness.